Search results
Showing 31 to 45 of 52 results for leiomyoma
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
allows concomitant treatment of intrauterine pathologies such as submucosal fibroids and endometrial polyps. It also facilitates the...
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
This guideline covers diagnosing and managing endometriosis, including where fertility is a priority. It aims to raise awareness of endometriosis symptoms, and to provide clear advice on referral, diagnosis and the range of treatments available.
Hysteroscopic morcellation of uterine leiomyomas (fibroids) (IPG522)
This guidance has been updated and replaced by NICE interventional procedures guidance 704.
This guidance has been updated and replaced by NICE HealthTech guidance 240.
This guidance has been updated and replaced by NICE HealthTech guidance 240.
Interventional procedures, IPG367 - Issued: November 2010 --> We have moved interventional procedures guidance 367 to become HealthTech guidance 240. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE interventional procedures guidance 522.
Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)
This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.
Laparoscopic removal of uterine fibroids with power morcellation (IPG703)
We have moved interventional procedures guidance 703 to become HealthTech guidance 589. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.
Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids (IPG689)
We have moved interventional procedures guidance 689 to become HealthTech guidance 572. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids (IPG704)
We have moved interventional procedures guidance 704 to become HealthTech guidance 590. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids (IPG231)
This guidance has been updated and replaced by NICE HealthTech guidance 277.